# GlaxoSmithKline: portfolio, investments and team > GlaxoSmithKline is a vc firm based in United States. 21 investments on record, latest Apr 2019. Portfolio, stages, co-investors and team. Source: https://millionrounds.com/fund/glaxosmithkline (Millionrounds; every figure on the page links to its filing or article) United States · [Investor](https://millionrounds.com/investors) # GlaxoSmithKline Last cheque observed Apr 2019. Silence since then is not evidence of inactivity: our sources miss unannounced rounds. Quiet VC firm Series A Venture Series B Analytics Apps Cloud Data Services Cheques on record **0%** of best year **0** **cheques in 12 months**, 21 on record Since the last cheque **2765** days **00** hrs **00** min **00** sec Median round **$125M** Rounds led **0 of 21** Sole investor **6 rounds** Exits **2 from the portfolio** Mostly in **United States, 75%** Pitch GlaxoSmithKline ## GlaxoSmithKline highlights - 01 21 rounds on record - 02 Mostly Series A and Venture: 74% of its rounds - 03 Sole investor in 6 rounds, median $17M - 04 2 exits from the portfolio ## What they do - **Type:** VC firm (from a list, unverified) - **Cheque size:** Not stated - **Sectors:** Analytics Apps Cloud Data Services - **Based in:** London, United States - **Cold pitches:** Not stated ## The record Every round we can evidence, newest first **21 appearances** - **2019** 1 round - **Apr** **[SpringWorks Therapeutics](https://millionrounds.com/company/springworks-therapeutics)** Series B · US · FinSMEs **$125M** With 12 others - **2018** 2 rounds - **Oct** **[Sitryx](https://millionrounds.com/company/sitryx)** GB · Pharmatimes **$30M** With 2 others - **Jul** **[23andMe](https://millionrounds.com/company/23andme)** US · Forbes **$300M** Sole investor - **2015** 6 rounds - **Nov** **[Atreca](https://millionrounds.com/company/atreca)** Series A · US **$56M** With 2 others - **Oct** **[Decibel Therapeutics](https://millionrounds.com/company/decibel-therapeutics)** Series A **$52M** With 2 others - **Jun** **[Gladius Pharmaceuticals](https://millionrounds.com/company/gladius-pharmaceuticals)** Series A · CA **$3.3M** With 3 others - **Jun** **[Spero Therapeutics](https://millionrounds.com/company/spero-therapeutics)** Series A · US **$30M** With 7 others - **Apr** **[CRISPR THERAPEUTICS](https://millionrounds.com/company/crispr-therapeutics)** Series B · GB **$64M** With 5 others - **Apr** **[ZappRx](https://millionrounds.com/company/zapprx)** Series A · US **$5.6M** With 2 others - **2014** 3 rounds - **Sept** **[Silarus Therapeutics](https://millionrounds.com/company/silarus-therapeutics)** Series A · US **$10M** With 1 other - **Sept** **[Thyritope Biosciences](https://millionrounds.com/company/thyritope-biosciences)** Series A · US **$10M** With 1 other - **Jul** **[Isis Pharmaceuticals](https://millionrounds.com/company/isis-pharmaceuticals)** Venture · US **$11M** Sole investor - **2013** 2 rounds - **Nov** **[Sitari Pharmaceuticals](https://millionrounds.com/company/sitari-pharmaceuticals)** Series A · US · finsmes.com **$10M** With 1 other - **Aug** **[SetPoint Medical](https://millionrounds.com/company/setpoint-medical)** Series A · US · sec.gov **$31M** With 6 others - **2011** 2 rounds - **Oct** **[Epizyme](https://millionrounds.com/company/epizyme)** Venture · US · epizyme.com **$4.0M** Sole investor - **Jun** **[Concert Pharmaceuticals](https://millionrounds.com/company/concert-pharmaceuticals)** Venture · US · masshightech.com **$4.0M** Sole investor - **2010** 3 rounds - **Dec** **[Semprus BioSciences](https://millionrounds.com/company/semprus-biosciences)** Series B · US · semprusbio.com **$18M** With 4 others - **Nov** **[Theravance](https://millionrounds.com/company/theravance)** Growth · US · files.shareholder.com **$129M** Sole investor - **May** **[NeuroTherapeutics Pharma](https://millionrounds.com/company/neurotherapeutics-pharma)** Series B · US · fiercebiotech.com **$43M** With 4 others - **2009** 2 rounds - **Oct** **[Genmab](https://millionrounds.com/company/genmab)** Venture · DK · fiercebiotech.com **$23M** Sole investor - **Jun** **[Chroma Therapeutics](https://millionrounds.com/company/chroma-therapeutics)** Venture · GB **$25M** With 5 others An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor. ## The team We hold **22** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them. ## What they claim to have backed From their own portfolio page (on their website) **0** of 3 we have independently watched raise Gskpro Supplier ViiV Healthcare Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded. ## Exits from the portfolio Companies it backed that were later bought or listed **2 in all** **[Epizyme](https://millionrounds.com/company/epizyme)** Listed **$60M** May 2013 **[Semprus BioSciences](https://millionrounds.com/company/semprus-biosciences)** Bought by Teleflex **$30M** Jun 2012 An exit counts when it came after the firm's first round in the company. From historical deal records. ## Companies it bought Acquisitions by the firm itself **[Okairos](https://millionrounds.com/company/okairos)** **$325M** May 2013 **Human Genome Sciences** **$3.0B** Aug 2012 **[NovaMin Technology](https://millionrounds.com/company/novamin-technology)** **Undisclosed** May 2010 **Stiefel** **$3.6B** Apr 2009 **[Genelabs Technologies](https://millionrounds.com/company/genelabs-technologies)** **$57M** Nov 2008 **[Sirtris Pharmaceuticals](https://millionrounds.com/company/sirtris-pharmaceuticals)** **$720M** Apr 2008 **[Reliant Pharmaceuticals](https://millionrounds.com/company/reliant-pharmaceuticals)** **$1.6B** Nov 2007 **CNS** **Undisclosed** Dec 2006 ## The cheque Series A Venture Series B Median round joined **$125M** the round, not its cheque Alone, median **$17M** Led 0 of 21 rounds **0%** - **Sole investor:** 6 rounds - **Last cheque:** Apr 2019 - **Exits:** 2 from the portfolio Rounds by stage said on their site - Series A *9* - Venture *5* - Series B *4* - Growth *1* Cheques by year Led Joined 2009 2019 Often in the room with - [SR One](https://millionrounds.com/fund/sr-one) 7 - [Avalon Ventures](https://millionrounds.com/fund/avalon-ventures) 3 - [Abingworth](https://millionrounds.com/fund/abingworth) 2 - [Atlas Venture](https://millionrounds.com/fund/atlas-venture) 2 - [Foundation Medical Partners](https://millionrounds.com/fund/foundation-medical-partners) 2 **Pitching GlaxoSmithKline?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque. Add to your CRM *→* ## Who they invest alongside The investors most often in the same rounds as GlaxoSmithKline. A count of rooms they were both in, not a relationship either has claimed. [**SR One** Corporate VC **7** rounds together](https://millionrounds.com/fund/sr-one)[**Avalon Ventures** VC firm **3** rounds together](https://millionrounds.com/fund/avalon-ventures)[**Abingworth** VC firm **2** rounds together](https://millionrounds.com/fund/abingworth)[**Atlas Venture** VC firm **2** rounds together](https://millionrounds.com/fund/atlas-venture)[**Foundation Medical Partners** Private equity **2** rounds together](https://millionrounds.com/fund/foundation-medical-partners) ## Recently backed The latest companies GlaxoSmithKline put money into. [**SpringWorks Therapeutics** $125M · Apr 2019](https://millionrounds.com/company/springworks-therapeutics)[**Sitryx** $30M · Oct 2018](https://millionrounds.com/company/sitryx)[**23andMe** $300M · Jul 2018](https://millionrounds.com/company/23andme) ## Quick answers about GlaxoSmithKline ### What does GlaxoSmithKline invest in? GlaxoSmithKline invests most often at Series A and Venture (74% of the rounds on record), in sectors such as Analytics, Apps and Cloud Data Services. ### How active is GlaxoSmithKline? 21 investments on record, 0 of them in the last 12 months. The most recent was in Apr 2019. ### What has GlaxoSmithKline invested in recently? Its most recent investments on record: SpringWorks Therapeutics (Series B, Apr 2019), Sitryx (Undisclosed round, Oct 2018) and 23andMe (Undisclosed round, Jul 2018). ### How big are GlaxoSmithKline's cheques? The median round it joins is $125M. ### Does GlaxoSmithKline lead rounds? Rarely, if at all: none of its 21 investments on record names it as the lead. ### Where does GlaxoSmithKline invest? Most of the companies it backs are in the United States (75%), the United Kingdom (15%) and Canada (5%). ### Is GlaxoSmithKline investing now? No investments in the last 12 months; the latest was in Apr 2019. ### Who does GlaxoSmithKline invest alongside? Most often SR One (7 rounds together), Avalon Ventures (3 rounds together) and Abingworth (2 rounds together). ## Raising now? Find the investors who back rounds like yours, and keep every conversation on one fundraising board. Find similar investorsOpen your CRM Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=glaxosmithkline) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=glaxosmithkline)